<DOC>
	<DOCNO>NCT00732745</DOCNO>
	<brief_summary>RATIONALE : Vandetanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , oxaliplatin docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether vandetanib effective placebo give together oxaliplatin docetaxel treat advanced cancer esophagus gastroesophageal junction . PURPOSE : This randomized phase I/II trial study side effect best dose vandetanib give together oxaliplatin docetaxel see well work treat patient advanced cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>Vandetanib , Oxaliplatin , Docetaxel Advanced Cancer Esophagus Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose vandetanib administer oxaliplatin docetaxel patient advance cancer esophagus gastroesophageal junction . ( Phase I ) - To evaluate toxicity regimen patient . ( Phase I ) - To determine progression-free survival patient . ( Phase II ) Secondary - To determine response rate patient treat oxaliplatin docetaxel without vandetanib . ( Phase II ) - To determine overall survival patient treat regimen . ( Phase II ) - To determine toxicity regimens patient . ( Phase II ) - To determine whether tumor characteristic ( e.g. , EGFR/ErbB2 expression , activation mutational status EGFR ErbB2 pathway [ total phosphorylated EGFR ErbB2 , mutational FISH analysis ] tumoral expression HIF1-alpha ) may association response outcome . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study vandetanib follow randomized phase II study . Patients stratify accord histology ( adenosarcoma vs squamous cell carcinoma ) prior neoadjuvant/adjuvant chemotherapy/chemoradiotherapy ( yes v ) . Patients randomize 1 2 treatment arm . Patients phase I receive treatment phase II arm I . - Phase II arm I : Patients receive docetaxel IV 1 hour day 1 8 , oxaliplatin IV 2 hour day 1 , oral vandetanib ( maximum tolerate dose determine phase I ) daily day 1-21 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients respond stable disease may continue receive vandetanib beyond 8 course absence disease progression unacceptable toxicity . - Phase II arm II : Patients receive docetaxel oxaliplatin arm I . Patients also receive oral placebo daily day 1-21 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients respond stable disease may continue receive vandetanib beyond 8 course absence disease progression unacceptable toxicity . Patients enrol phase II submit baseline tumor tissue sample correlative laboratory study , include analysis EGFR ErbB2 mutational , FISH , IHC analysis HIF1-alpha expression IHC analysis .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced adenocarcinoma squamous cell carcinoma esophagus gastroesophageal junction Patients locally advance , unresectable disease eligible provide failed prior radiationbased therapy At least one measurable lesion No active CNS metastasis indicate clinical symptom , cerebral edema , progressive growth Patients clinical history CNS metastases cord compression eligible provide definitively treat clinically stable ≥ 4 week ( treated whole brain irradiation ) ≥ 2 week ( treat gamma knife therapy ) PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 12 week Hemoglobin &gt; 9.5 g/dL ANC &gt; 1,500/μL Platelets &gt; 100,000/μL Total bilirubin normal Creatinine &lt; 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 30 mL/min AST , ALT , alkaline phosphatase ( AP ) must meet one follow criterion : AST ALT ≤ 5 time ULN AND AP normal AST ALT ≤ 1.5 time ULN AND AP ≤ 2.5 time ULN AST ALT normal AND AP ≤ 5 time ULN Potassium 4 mmol/L upper limit CTCAE grade 1 ( supplementation allow ) Calcium ( ionize adjust albumin ) magnesium normal ( supplementation allow ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No significant cardiovascular event within past 3 month , include follow : Myocardial infarction Superior vena cava syndrome NYHA class IIIV congestive heart failure No cardiac disease , opinion investigator , may increase risk ventricular arrhythmia No prior arrhythmia ( e.g. , multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) Atrial fibrillation allow provide controlled medication No asymptomatic sustain ventricular tachycardia No hypertension control medical therapy ( i.e. , systolic blood pressure [ BP ] &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg ) No QTc prolongation medication require discontinuation medication No congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age QTc &lt; 480 Bazett 's correction screen ECG baseline No presence leave bundle branch block No active diarrhea &gt; CTC grade 1 No prior severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No prior allergic reaction compound similar chemical biologic composition study drug No severe acute chronic medical psychiatric condition laboratory abnormality , opinion investigator , would preclude study participation No malignancy within past 5 year , except curatively treat basal cell carcinoma skin , cervical intraepithelial neoplasia , localized prostate cancer current PSA &lt; 1.0 mg/dL 2 successive evaluation ≥ 3 month apart , recent evaluation perform within past 4 week No peripheral neuropathy &gt; grade 1 No blood donation 3 month completion study treatment No severe uncontrolled systemic disease medical condition , include mental illness substance abuse , would preclude study participation PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior systemic therapy metastatic disease Prior chemotherapy give part definitive treatment plan ( e.g. , neoadjuvant adjuvant chemotherapy concurrent chemoradiotherapy ) allow More 6 month since prior oxaliplatin docetaxel neoadjuvant adjuvant therapy More 4 week since prior major surgery , chemotherapy , radiotherapy , investigational agent , cancer therapy No prior antiVEGF EGFR therapy , include bevacizumab More 2 week since prior concurrent potent CYP3A4 inducer ( e.g. , rifampin , rifabutin , phenytoin , carbamazepine , phenobarbital , Hypericum perforatum [ St. John 's wort ] ) More 2 week since prior concurrent medication know cause QTc prolongation induce torsades de point No concurrent chemotherapy , systemic antineoplastic therapy , investigational therapy No concurrent radiotherapy , unless local control bone pain No concurrent cold cap ice mouth rinse prevention alopecia stomatitis No concurrent routine prophylactic use granulocyte colonystimulating factor ( GCSF ) pegfilgrastim No concurrent vitamin B6 supplementation , except part standard multivitamin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>